Finch Therapeutics

18 articles with Finch Therapeutics

• Finch Therapeutics Presents Data from Its Positive PRISM3 Trial of CP101 in Recurrent C. difficile Infection at Two Leading Medical Conferences

  10/28/2020

  Finch Therapeutics Presents Data from Its Positive PRISM3 Trial of CP101 in Recurrent C. difficile Infection at Two Leading Medical Conferences PRISM3 data presented at the annual meetings of the United European Gastroenterology and the American College of Gastroenterology Late-breaker oral presentations expand on previously announced positive topline data showing that CP101 met the primary efficacy endpoint with statistically significant improv

• Finch Therapeutics Announces $90 Million Financing to Advance Pipeline of Investigational Oral Microbiome Drugs

  9/17/2020

  Proceeds to support the advancement of lead candidate through the final stages of clinical development for recurrent C. difficile infection, and the advancement into the clinic of programs for autism spectrum disorder and chronic hepatitis B SOMERVILLE, Mass.--( BUSINESS WIRE )-- Finch Therapeutics Group, Inc. (“Finch”), a clinical-stage microbiome drug development company, announced today a $90 million Series D financing. New investors in the roun

• 

  Finch Closes $90 Million Series D to Advance C. Difficile Infection Product

  9/17/2020

  The company plans to use the funds to advance its lead candidate CP101 for recurrent C. difficile infection through the final stages of clinical development and regulatory submission.

• Finch Therapeutics Announces Positive Topline Results from Randomized Controlled Trial of CP101, an Oral Microbiome Drug, for the Prevention of Recurrent C. difficile Infection

  6/19/2020

  CP101 met the primary efficacy endpoint with statistically significant improvement in the prevention of recurrent C. difficile infection over standard of care alone in a 206-patient trial

• 

  Finch's Live Microbiome Drug Shows Promise in C. Diff Treatment

  6/19/2020

  Finch Therapeutics reported positive topline results from PRISM3, its Phase II trial of CP101, an oral microbiome drug for the prevention of recurrent C. difficile infection.

• Finch Therapeutics Completes Enrollment in Potentially Pivotal Trial of CP101, an Investigational Oral Full-Spectrum Microbiota® Therapy for the Prevention of Recurrent C. difficile Infection

  1/8/2020

  Finch Therapeutics Group, Inc., a clinical-stage microbiome therapeutics company, announced that it has completed enrollment in PRISM3, its multi-center, placebo-controlled Phase 2 clinical trial evaluating CP101.

• Finch Therapeutics & Takeda Expand Collaboration to Develop Microbiome Therapeutics Using Finch’s Human-First Discovery® Platform

  11/13/2019

  Finch & Takeda to target Crohn’s disease under expanded collaboration

• Finch Therapeutics Announces Appointment of Dr. Jo Viney and Domenic Ferrante to its Board of Directors

  9/25/2019

  Finch Therapeutics Group, Inc., a clinical-stage microbiome therapeutics company, announced the appointment of Dr. Jo Viney and Domenic Ferrante to its Board of Directors.

• Finch Therapeutics Raises $53 Million to Advance Microbiome-Based Therapies for Recurrent C. Difficile, Autism and other Disease Areas

  8/22/2019

  Finch Therapeutics Group, Inc. announced the completion of a $53 million Series C financing.

• Finch Therapeutics Receives Fast Track Designation for the Investigation of Full-Spectrum Microbiota as a Treatment for Children with Autism Spectrum Disorder

  4/29/2019

  Finch Therapeutics Group, Inc. announced that the U.S. Food and Drug Administration has granted Fast Track designation to its Full-Spectrum Microbiota® therapy for the treatment of children with Autism Spectrum Disorder.

• Finch Therapeutics’ Investigational Drug CP101 Granted Breakthrough Therapy Designation from FDA for Recurrent C. Difficile Infection

  2/8/2019

  Designation to accelerate Finch’s efforts to provide an effective therapy for patients fighting recurrent C. difficile infection.

• 

  Longevity Company Unity Biotechnology Stocks Soared After CEO Talks to CNBC

  9/14/2018

  After Unity Biotechnology chief executive officer Keith Leonard was on CNBC’s “Power Lunch,” touting the company’s therapeutic approach to longevity and aging, company shares soared almost 18 percent.
• 

  Elevian Launches to Join Numerous Companies Focused on Longevity and Aging

  9/10/2018

  In another example of companies focused on aging-related diseases, Elevian launched with $5.5 million in seed funding. Elevian’s founders came out of Stanford and then Harvard, focused on regenerative effects of “young blood.”

• Finch Therapeutics Expands Its Leading Microbiome IP Estate with Six New Patents

  7/25/2018

  Finch Therapeutics Group, Inc. announced that the U.S. Patent and Trademark Office (USPTO) has issued six new patents to Finch covering its Full-Spectrum Microbiota (FSM) and Rationally-Selected Microbiota (RSM) product platforms.

• Finch Therapeutics Expands Senior Leadership Team with Appointments of Dr. Ulrich Thienel as Chief Medical Officer and Gregory Perry as Chief Financial Officer

  6/12/2018

  Dr. Thienel will lead the clinical development of Finch’s Full-Spectrum Microbiota™ and Rationally-Selected Microbiota™ platforms, while Mr. Perry will provide strategic financial and operational leadership at Finch.

• 

  Finch Therapeutics Raises $36 Million Series B, Bringing Total to $77 Million

  3/1/2018

  Finch Therapeutics closed on an oversubscribed Series B financing worth $36 million.
• 

  Takeda's Partner Merges With Crestovo to Form Finch Therapeutics Group

  10/23/2017

  Two privately-held biotechs have merged to tackle recurrent C. difficile infections.

• OpenBiome Partnering With Finch Therapeutics To Enable FDA Approval Of A Fecal Transplant Treatment For Recurrent C. Difficile Infection

  2/23/2017